Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SAVAYSA | Daiichi Pharmaceutical | N-206316 RX | 2015-01-08 | 3 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
savaysa | New Drug Application | 2024-02-06 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
venous thrombosis | — | D020246 | I82.40 |
pulmonary embolism | EFO_0003827 | D011655 | I26 |
Expiration | Code | ||
---|---|---|---|
EDOXABAN TOSYLATE, SAVAYSA, DAIICHI SANKYO INC | |||
2026-10-18 | M-14 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 3 | 6 | 4 | 10 | 23 |
Thrombosis | D013927 | — | — | 1 | 5 | 3 | 1 | — | 10 |
Embolism | D004617 | — | — | — | 1 | 4 | 1 | — | 6 |
Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | 2 | 1 | 1 | 5 |
Coronary artery disease | D003324 | — | I25.1 | — | 1 | 1 | 3 | — | 4 |
Hemorrhage | D006470 | MP_0001914 | R58 | 1 | — | — | 1 | — | 2 |
Coronary disease | D003327 | — | — | — | — | — | 2 | — | 2 |
Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | 2 | — | 2 |
Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | — | 1 | — | 1 |
Acute coronary syndrome | D054058 | EFO_0005672 | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Thromboembolism | D013923 | — | — | 1 | 3 | 7 | — | 3 | 14 |
Venous thromboembolism | D054556 | EFO_0004286 | I74 | 1 | 2 | 7 | — | 3 | 13 |
Venous thrombosis | D020246 | — | I82.40 | 1 | 3 | 3 | — | — | 7 |
Pulmonary embolism | D011655 | EFO_0003827 | I26 | — | — | 3 | — | — | 3 |
Ischemic stroke | D000083242 | — | — | — | — | 1 | — | 1 | 2 |
Renal insufficiency | D051437 | — | N19 | — | — | 2 | — | — | 2 |
Aortic valve stenosis | D001024 | EFO_0000266 | — | — | — | 1 | — | — | 1 |
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 1 | — | — | 1 |
Neoplasms | D009369 | — | C80 | — | — | 1 | — | — | 1 |
Hip fractures | D006620 | EFO_0003964 | S72.00 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Replacement arthroplasty hip | D019644 | — | — | — | 2 | — | — | — | 2 |
Peripheral arterial disease | D058729 | EFO_0004265 | — | — | 1 | — | — | — | 1 |
Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | — | 1 | — | — | — | 1 |
Embolism and thrombosis | D016769 | — | — | — | 1 | — | — | — | 1 |
Replacement arthroplasty knee | D019645 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Ischemia | D007511 | EFO_0000556 | — | — | — | — | — | 1 | 1 |
Cerebral infarction | D002544 | — | I63 | — | — | — | — | 1 | 1 |
Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 1 | 1 |
Drug common name | Edoxaban |
INN | edoxaban |
Description | Edoxaban is a monocarboxylic acid amide that is used (as its tosylate monohydrate) for the treatment of deep vein thrombosis and pulmonary embolism. It has a role as an anticoagulant, an EC 3.4.21.6 (coagulation factor Xa) inhibitor and a platelet aggregation inhibitor. It is a monocarboxylic acid amide, a chloropyridine, a thiazolopyridine and a tertiary amino compound. It is a conjugate base of an edoxaban(1+). |
Classification | Small molecule |
Drug class | antithrombotics, blood coagulation factor XA inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1 |
PDB | — |
CAS-ID | 480449-70-5 |
RxCUI | — |
ChEMBL ID | CHEMBL1269025 |
ChEBI ID | 85973 |
PubChem CID | 10280735 |
DrugBank | DB09075 |
UNII ID | NDU3J18APO (ChemIDplus, GSRS) |